Epidemiology Dataset | Aggregated & Synthetic Population Health Data for Germany

The Challenge Keeping Market Access Teams Up at Night

Look, if you’ve ever tried sizing a Continental European market opportunity or preparing a reimbursement submission with incomplete data, you know the frustration. Clinical trials give you efficacy—brilliant, controlled, pristine data. But they don’t tell you what happens when your 75-year-old diabetic patient with three comorbidities walks into a real clinic in routine practice.

That’s where epidemiology datasets come in. And honestly? Continental Europe’s statutory health insurance systems might just be the gold standard for this kind of population health intelligence.

We’re talking about aggregated insurance claims data covering hundreds of millions of lives across the continent—longitudinal tracking, diagnosis codes (ICD-10), procedure codes, prescription patterns (ATC classification), and actual healthcare utilization patterns across all major regions. This isn’t survey data or extrapolated estimates. It’s comprehensive, real-world evidence derived from the administrative records of some of the world’s most robust healthcare systems.

For pharma, biotech, and MedTech companies trying to understand disease burden, treatment pathways, or market dynamics in Continental Europe, these datasets have become absolutely essential. The regulatory environment is tightening—EHDS, evolving HTA requirements, and reimbursement reforms all point in the same direction—and decision-makers increasingly demand real-world evidence alongside clinical trial data.

But here’s what most teams miss: not all epidemiology data is created equal. The difference between representative, validated, analysis-ready datasets and fragmented, hard-to-access claims data can determine whether your HTA dossier succeeds or your market forecast misses by 40%. And the gap between knowing which data exists and identifying which source actually fits your strategic needs? That’s where most companies struggle.

What Enterprise Buyers Need to Know About Epidemiology Datasets

Let me break down what we actually mean when we talk about epidemiology datasets in the Continental European context—because the terminology can get muddy fast.

Epidemiology datasets are structured collections of health-related data used to study disease distribution, determinants, and outcomes across populations. In Continental Europe, the most comprehensive and reliable epidemiology data comes from statutory health insurance (SHI) claims—administrative records generated every time an insured person receives medical care, fills a prescription, or undergoes a procedure.

This is fundamentally different from clinical trial data (tightly controlled and narrowly defined) or survey data (which relies on self-reporting and suffers from response bias). Claims data captures what actually happens in routine clinical practice, warts and all.

Within the epidemiology dataset category, you’ll typically encounter three main types:

1. Individual-Level Claims Data

The most granular form—pseudonymized patient-level records that allow longitudinal tracking of treatment patterns, outcomes, and healthcare utilization over time. This is what you need for sophisticated analyses like treatment sequencing, time-to-event studies, or adherence research. Access is heavily restricted under GDPR Article 9 protections on special category health data, requiring extensive legal review, data protection impact assessments, and often multi-month approval processes across each jurisdiction.

2. Aggregated Population Health Data

Pre-processed, de-identified datasets where individual records have been aggregated to prevent re-identification. You might get prevalence rates by age group, region, and diagnosis code—or treatment patterns summarized at cohort level. The advantage is faster access with reduced regulatory friction. You’re working with statistical summaries that still preserve enormous analytical value for market sizing, epidemiological burden studies, and comparative analyses. The European Medicines Agency’s framework on real-world evidence increasingly supports the use of aggregated claims for regulatory decision-making—an important signal for how the landscape is evolving.

3. Synthetic Healthcare Data

Generated from real-world claims using advanced techniques like Generative Adversarial Networks (GANs) with differential privacy guarantees. Synthetic data preserves the statistical properties and correlations of the original dataset but contains zero actual patient records—and therefore isn’t subject to GDPR personal data restrictions. You can share it across teams and borders, use it for algorithm training, or distribute it for educational purposes without regulatory constraints. Official research initiatives have demonstrated that synthetic data is becoming a cornerstone of privacy-preserving health research across Continental Europe.

Understanding which of these data types fits your specific use case—and which source within each type offers the right combination of coverage, quality, and accessibility—requires more than a quick vendor evaluation. The nuances matter enormously, and the wrong choice at the data selection stage creates downstream problems that are expensive to fix.

Continental European Healthcare Systems: Why They Produce World-Class Epidemiology Data

Continental Europe’s statutory health insurance systems aren’t just big—they’re methodical, standardized, and shockingly comprehensive by international standards.

Countries across Continental Europe—including France, the Netherlands, Switzerland, Austria, Belgium, and their neighbors—maintain near-universal or universal statutory health insurance coverage. Everyone from newborns to centenarians, from healthy individuals to those with complex chronic conditions, generates standardized administrative data continuously.

What makes this extraordinary for epidemiological research is the standardization. Diagnoses are coded using ICD-10 or national adaptations. Procedures follow standardized coding systems. Prescriptions are classified by ATC code. All of this is captured digitally, consistently, across broad population segments.

Compare this to markets where healthcare data is fragmented across dozens of private insurers, public programs, uninsured populations, and inconsistent coding standards. Continental Europe’s combination of near-universal coverage, standardized coding, and digital administrative infrastructure creates an epidemiological foundation that simply doesn’t exist in most comparable markets.

Research validating the representativeness of major Pan-European claims databases consistently confirms that these datasets accurately reflect the population’s age, sex, morbidity, and mortality distributions. This isn’t modeled data or a convenience sample—it’s population-representative real-world evidence with documented validation.

Continental Europe also offers regional granularity—distinct geographic areas across multiple countries, each with their own demographics, prescribing cultures, and healthcare infrastructure. For regional launch strategies or prescriber targeting, this level of specificity is genuinely valuable and rarely available at comparable quality elsewhere globally.

Sources and Types of Epidemiological Data Available in Continental Europe

When evaluating epidemiology datasets for a Pan-European project, understanding the major source categories—and what each contributes—is essential groundwork.

Statutory Health Insurance (SHI) Claims Data

The foundation of Pan-European population health research. Administrative records from SHI systems across the continent capture diagnoses, prescriptions, procedures, hospital admissions, outpatient visits, and medical device usage. Major research databases in this space aggregate claims from multiple insurers across countries, covering tens of millions of lives with longitudinal follow-up. Strengths include longitudinal depth, completeness, and population representativeness. The limitation: administrative codes are optimized for billing, not clinical research—so granular clinical nuances like biomarker data or detailed lab values may be absent or limited.

Hospital Data (DRG and Equivalent Data)

Diagnosis Related Groups and equivalent inpatient classification systems across Continental Europe generate detailed inpatient data: primary and secondary diagnoses, procedures, length of stay, and discharge outcomes. Particularly valuable for understanding inpatient treatment patterns, surgical interventions, and hospital resource utilization. When combined with SHI claims, this data enables a comprehensive view of both inpatient and outpatient care—critical for oncology, cardiology, and other hospital-intensive therapeutic areas.

Disease Registries

For specific conditions—cancer, infectious diseases, rare diseases—Continental European countries maintain national and regional registries with more granular clinical detail than standard claims. Cancer registries include staging, histology, treatment regimens, and outcomes. Access is typically more restricted than claims data and requires separate negotiations. But when clinical depth matters for a specific disease, registries are unmatched.

Public Health Surveillance Systems

National public health institutes and the European Centre for Disease Prevention and Control (ECDC) operate surveillance systems for reportable infectious diseases, vaccination coverage, and population health monitoring. These complement claims data with epidemiological context and prevention insights that administrative data alone can’t provide.

Prescription Data

Standalone prescription data sources track medication dispensing patterns, adherence, and utilization—particularly valuable for commercial analytics teams monitoring market share, brand versus generic dynamics, or prescribing patterns by specialty.

The most sophisticated epidemiological research typically combines multiple source types. But this creates its own complexity: each source has distinct access requirements, governance structures, and analytical strengths. Knowing when to use each—and how to combine them effectively—is where expertise becomes the differentiating factor.

Real-World Evidence and Its Growing Role in Pan-European Healthcare Decisions

Real-world evidence has moved from “nice to have” to mission-critical for regulatory and reimbursement success across Continental Europe. And this shift has teeth.

Health technology assessment (HTA) bodies across Continental Europe—including national committees in France (HAS), the Netherlands (ZIN), Switzerland (BAG/OFSP), Belgium (INAMI/RIZIV), and others—increasingly mandate post-approval data collection and RWE generation, especially for high-cost therapies, orphan drugs, and products with conditional approvals. Landmark decisions requiring ongoing RWE collection for advanced therapies like gene treatments aren’t isolated cases—they reflect a systematic regulatory expectation that real-world performance must be documented and evidenced.

The EMA has moved in the same direction. Their DARWIN EU initiative explicitly leverages Pan-European claims data as a core source for post-marketing surveillance, effectiveness studies, and safety monitoring. The EMA’s 2023 framework report makes it clear: RWE derived from high-quality administrative data is now considered valid and valuable for regulatory decision-making, particularly for rare diseases, oncology, and long-term safety assessments.

For reimbursement submissions, payers and HTA bodies are demanding evidence of real-world effectiveness and comparative outcomes. Clinical trial efficacy data alone isn’t sufficient when trial populations don’t reflect the heterogeneity of actual patients across Continental European healthcare systems.

If you’re launching a product in Continental Europe, epidemiology datasets are needed to:

Size your patient population accurately using real prevalence and incidence data, not top-down epidemiological models
Understand current treatment patterns and identify unmet needs or treatment gaps
Design comparative effectiveness studies with control groups reflecting Pan-European standard of care
Support budget impact models with real-world healthcare utilization and cost data
Identify appropriate prescribers and treatment centers based on claims-derived referral patterns
Monitor post-launch performance against HTA body mandates for ongoing evidence generation

The companies getting this right embed real-world evidence strategies from Phase II onwards—not scrambling to generate RWE after launch when HTA bodies ask for it. The challenge many teams face isn’t recognizing that RWE matters. It’s determining which data combination, analytical approach, and evidence strategy aligns with their specific product, indication, and regulatory context.

Key Use Cases: How Pharma, Biotech, and MedTech Actually Use These Datasets

Here are the most common—and strategically valuable—applications for enterprise clients working with Pan-European epidemiology datasets.

Disease Burden Estimation and Incidence/Prevalence Studies

Foundational work for any market entry or therapeutic area strategy. Analyses of hematological malignancies and other conditions using Pan-European claims data demonstrate how researchers calculate accurate diagnosed prevalence, incidence rates, age and sex distributions, and regional variations from administrative data. For rare diseases—where clinical trial recruitment is challenging and published epidemiological literature is scarce—claims data often provides the only reliable prevalence estimates. Studies on rare neurological conditions have used SHI claims across Continental Europe to identify patient populations and characterize healthcare utilization in ways impossible with traditional methods.

Treatment Patterns and Adherence Analysis

What happens after diagnosis? Which therapies do patients receive, in what sequence, and how long before switching or discontinuing? Claims data excels here because it captures actual prescriptions filled and healthcare encounters over time. This is critical for understanding real-world treatment pathways (which frequently differ from guidelines), estimating market share dynamics, and identifying where a new product fits in the treatment sequence.

Health Economics and Outcomes Research (HEOR)

Market access and reimbursement require health economic models grounded in country-specific data. Claims datasets provide inputs: treatment costs, hospitalization rates, complication frequencies, healthcare resource utilization, and long-term outcomes. Burden-of-illness analyses using Pan-European claims data demonstrate the analytical depth possible when estimating economic impact—directly informing reimbursement discussions with payers and HTA bodies across the continent.

Pharmacovigilance and Safety Monitoring

Post-marketing surveillance requirements demand population-scale safety monitoring. Claims data enables detection of adverse events, drug interactions, off-label use patterns, and long-term safety signals that don’t emerge in trials—particularly valuable for products with restricted indications or complex dosing requirements.

Market Access and Forecasting

Every commercial analytics team needs accurate patient population estimates, treatment uptake projections, and competitive intelligence. Claims data provides the foundation: diagnosed prevalence by severity and stage, treatment patterns by line of therapy, prescribing dynamics by specialty and region, and loss-of-exclusivity impact when generics enter.

Clinical Trial Feasibility and External Control Arms

Before initiating trials in Continental Europe, sponsors need feasibility assessments: sufficient eligible patients, geographic concentration, site experience. Claims data answers these questions. Increasingly, regulators also accept external control arms derived from claims data for rare diseases or situations where randomized controls are ethically or practically challenging.

These aren’t academic exercises. They are mission-critical analyses that directly impact regulatory approval, reimbursement outcomes, and commercial performance in one of the world’s largest pharma markets. And the difference between insight and noise often comes down to whether the right data source was selected for the right question from the start.

Navigating the Data Landscape: What to Look For

The Pan-European epidemiology data market includes a range of providers with overlapping but meaningfully distinct capabilities. Understanding the dimensions of variation—rather than defaulting to the most visible or most marketed option—is how sophisticated buyers make decisions that hold up over time.

Coverage and Representativeness

Some providers maintain broad longitudinal coverage across full insured populations in multiple countries, enabling population-representative analyses. Others focus on specific regions, therapeutic areas, or payer segments with greater clinical depth. The right choice depends on whether your use case demands breadth (market sizing, epidemiology) or depth (clinical pathway analysis, outcomes research).

Data Recency and Update Frequency

Claims data is inherently retrospective due to adjudication timelines—but the lag varies significantly across providers, countries, and data types. For commercial monitoring and launch analytics, recency matters enormously. For long-term safety studies or historical prevalence analysis, a slightly older but more complete dataset may be preferable.

Analytical Capabilities and Delivery Models

Some providers offer full-service analytical platforms with self-service query tools. Others deliver structured datasets for internal analysis teams. Some offer managed analytics services where their experts run studies on your behalf. The right model depends on your internal analytical capabilities, turnaround requirements, and budget structure.

GDPR Compliance Infrastructure

GDPR compliance is non-negotiable when working with health data across Continental Europe. Under GDPR Article 9, health data is classified as special category personal data requiring explicit legal basis, documented data protection impact assessments (DPIAs), and robust technical and organizational measures. This applies uniformly across all EU member states and EEA countries. Providers vary significantly in how rigorously they’ve implemented and documented compliance infrastructure. Evaluating this thoroughly—before signing any data licensing agreement—is essential. Additionally, non-EU European countries such as Switzerland have their own national data protection legislation (nDSG) that aligns closely with GDPR principles but requires separate legal review.

Therapeutic Area Depth

Coverage breadth across disease areas varies. Some providers have particularly strong coverage in oncology, others in cardiovascular or rare disease. Validating that a dataset has sufficient patient volume in your specific indication—before committing to a licensing arrangement—prevents expensive downstream disappointments.

Integration and Interoperability

Can the data be linked with other sources you’re already using? What formats and delivery mechanisms are supported? API access, standard coding schema documentation, and compatibility with analytical tools your team already uses are practical considerations that significantly affect time-to-insight.

The challenge most pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities aligns with their strategic priorities. Understanding which sources match specific use cases requires deep market knowledge that most companies lack internally. This is precisely where expert advisory guidance accelerates decision-making and prevents costly mismatches.

Advantages of Aggregated and Synthetic Data: Privacy, Speed, and Innovation

GDPR Article 9 classifies health data as special category personal data requiring the highest level of protection. This regulation applies across all EU member states and, with equivalent national legislation, across the broader Continental European region. Accessing pseudonymized, patient-level claims data is legally possible—but demands extensive contracts, DPIAs, ethical approvals, and often months of legal review in each relevant jurisdiction.

This is where aggregated and synthetic data fundamentally changes the strategic calculus.

Aggregated Data: Fast Access, Reduced Risk

When data is aggregated to population-level summaries (prevalence rates by age group and region, treatment patterns at cohort level), it no longer qualifies as personal data under GDPR. Re-identification risk is eliminated. You retain population-representative insights for market sizing, epidemiological assessments, and strategic planning—but get them in days or weeks, not months. For preliminary analyses, hypothesis generation, or strategic questions where patient-level granularity isn’t essential, aggregated data delivers the right balance of utility and accessibility.

Synthetic Data: Full Privacy, Full Innovation Potential

Synthetic healthcare data generated using techniques like Generative Adversarial Networks (GANs) with differential privacy guarantees preserves statistical properties and correlations of real claims data while containing zero actual patient records. This means synthetic data isn’t subject to GDPR personal data restrictions at all. Applications expanding rapidly include:

Machine learning development: Training diagnostic algorithms and prediction models without accessing real patient data
Scenario modeling: Testing “what-if” analyses for market entry, pricing strategies, or treatment pathway optimization
Hypothesis testing: Preliminary analyses before committing to expensive patient-level data access
Education and collaboration: Sharing datasets with academic partners or training internal data science teams across multiple countries without triggering cross-border GDPR transfer concerns

Synthetic data isn’t a perfect substitute for patient-level data in all contexts—particularly for complex longitudinal analyses or rare event detection. But for a growing range of applications, it’s genuinely transformative. Companies mastering synthetic data early are positioning themselves at the forefront of AI-enabled healthcare analytics.

Challenges in Epidemiological Research with Pan-European Data (And How to Address Them)

Working with Pan-European epidemiology datasets comes with real challenges. Acknowledging them honestly is part of making sound strategic decisions.

Data Access Barriers and Cross-Border Complexity

Accessing patient-level claims data across Continental Europe remains complex. Navigating GDPR, national data protection laws (each EU member state has implementing legislation; Switzerland has the nDSG; Norway and Iceland operate under the EEA Agreement), insurer negotiations, ethical approvals, and legal documentation can delay projects by 6–18 months for companies without established data partnerships in each market.

The practical approach: Start with aggregated or synthetic datasets for preliminary analyses, proceed to patient-level data only when essential, and invest in building data access infrastructure before you urgently need it.

Heterogeneity Across Healthcare Systems

Unlike a single-country dataset, Pan-European data spans meaningfully different healthcare systems—Bismarckian SHI models in France, Austria, Belgium, and the Netherlands; mixed systems in Switzerland and Scandinavia; and varying degrees of centralization. Coding standards, access policies, governance frameworks, and analytic capabilities differ across borders. Research databases that have already aggregated and harmonized data across multiple countries address this—but understanding which aggregated source covers which markets and how comparably requires detailed evaluation.

Missing Variables and Limited Clinical Detail

Claims data is optimized for billing, not clinical research. Detailed lab values, biomarker results, imaging findings, and patient-reported outcomes are generally absent. Severity staging is limited. For highly granular clinical questions, data linkage with registries or supplementary primary data collection may be necessary.

Linkage Difficulties Across Borders

Combining claims data with other sources is technically and legally challenging under GDPR—particularly for cross-border linkage. Federated analysis approaches—where queries run locally on each dataset without data transfer—are emerging as practical solutions, but aren’t yet universally available across data holders in all Continental European markets.

The Honest Bottom Line

These challenges are real but addressable with the right strategy and partnerships. The European Health Data Space (EHDS) is actively working to standardize secondary use of health data across the EU and reduce access barriers while maintaining privacy protections. The trajectory is clearly toward greater accessibility—but navigating the current landscape still requires expertise and patience.

Future Trends: Where Pan-European Population Health Data Is Headed

European Health Data Space (EHDS)

The EHDS regulation will reshape secondary use of health data across Europe—standardized access frameworks, cross-border data sharing under strict GDPR-aligned privacy protections, and reduced administrative burden for legitimate research. Pilot projects are already underway across multiple member states. Companies positioning themselves for EHDS infrastructure early will have meaningful competitive advantages in multi-country RWE generation.

Expanded Data Linkage

Continental Europe’s push toward electronic health records and enhanced health data infrastructure is enabling richer data linkage—combining claims with electronic prescribing records, vaccination registries, primary care data, and patient-reported outcomes. This will unlock precision medicine applications and real-time safety surveillance currently impossible with claims data alone.

AI and Machine Learning at Scale

As synthetic data generation matures and computational capabilities expand, AI applications will accelerate: predictive models for disease progression, treatment optimization algorithms, automated patient stratification for clinical trials, and real-time decision support. Companies investing now in AI-ready data infrastructure and synthetic data capabilities are building durable analytical advantages.

Federated Analytics

The shift toward federated analysis models—where algorithms travel to data rather than vice versa—will enable analyses across data sources in multiple countries that could never be physically combined. This preserves privacy, reduces cross-border GDPR transfer friction, and opens new research possibilities across the Continental European data landscape.

Greater Regulatory Acceptance of RWE

As HTA bodies, national payers, and the EMA accumulate experience with real-world evidence, more explicit methodology guidance and evidence standards will reduce uncertainty and enable more confident RWE investments. This evolution rewards companies that build RWE expertise systematically rather than reactively.

Why Continental Europe Is a Leading Source for High-Quality Epidemiological Insights

Continental Europe offers something genuinely rare in global healthcare data: near-universal or universal population coverage across multiple major markets, standardized coding systems, longitudinal tracking over years or decades, regional granularity, robust GDPR-compliant infrastructure, and a regulatory environment that increasingly demands and rewards real-world evidence.

For pharma, biotech, and MedTech companies, this translates directly to better market sizing, more successful HTA submissions, stronger regulatory packages, more accurate forecasting, and better commercial outcomes across the world’s most sophisticated healthcare markets.

The companies winning here share common traits: they start RWE planning in Phase II, not post-launch; they invest in long-term data strategies rather than one-off analyses; they combine data types strategically based on research questions; and they embed Pan-European data insights into global evidence strategies from the beginning.

Whether you’re sizing an indication, preparing an HTA submission, designing a post-marketing surveillance study, or building a long-term market access evidence base—Pan-European epidemiology datasets provide the foundation. The question isn’t whether to invest in this data. It’s whether you have the strategic guidance to use it effectively.

FAQ: Common Questions from HEOR and Market Access Teams

Q: How does Pan-European epidemiology data compare to other global markets in terms of coverage and quality?

Continental Europe offers substantially higher population coverage than most comparable markets globally, with statutory health insurance covering the vast majority of the population across major economies including France, the Netherlands, Switzerland, Austria, and Belgium. The combination of near-universal coverage, standardized coding, longitudinal depth, and regional granularity is genuinely exceptional by global standards—which is why it’s often the first region targeted for international RWE programs.

Q: Can we use Pan-European claims data for HTA early benefit assessments?

Increasingly, yes—and HTA bodies across the continent are moving in this direction systematically. Real-world evidence is accepted for indirect comparisons, long-term outcomes assessment, and subgroup analyses where randomized trial data is limited or unavailable. The key is ensuring your data source meets quality standards: population representativeness, validated coding, appropriate follow-up, and transparent methodology. Documentation discipline is essential, and requirements vary by country.

Q: What’s the typical timeline for accessing patient-level versus aggregated data?

Aggregated data from established providers: typically 2–4 weeks from initial request to delivery for standard use cases. Patient-level pseudonymized data: expect 3–12 months minimum, sometimes longer for complex cross-border projects or first-time access arrangements—timelines vary significantly by country. This timeline differential is one of the strongest practical arguments for starting with aggregated data.

Q: How do we ensure GDPR compliance when working with Pan-European health data?

Partner with providers who’ve already implemented GDPR-compliant infrastructure: documented anonymization/pseudonymization processes, data processing agreements (DPAs) covering each relevant jurisdiction, security measures (encryption, access controls), and established legal basis for processing under Article 9(2)(j) for scientific research. For cross-border data sharing, ensure appropriate transfer mechanisms are in place (adequacy decisions, standard contractual clauses, or binding corporate rules). Your organization also needs its own DPIAs and internal compliance documentation in each market. The compliance burden is shared—but both sides need to have done the work.

Q: Can synthetic data replace real claims data for our analyses?

It depends on the use case. For hypothesis generation, algorithm training, scenario modeling, and education—synthetic data is excellent and often preferable due to speed and privacy simplicity (no GDPR personal data restrictions apply). For regulatory submissions, complex longitudinal analyses, rare event detection, or high-precision requirements—real claims data remains necessary. Think of synthetic and real data as complementary tools in the same strategic toolkit.

Q: What therapeutic areas have the strongest data coverage in Pan-European claims databases?

Coverage is strong across nearly all areas, but particularly robust for chronic conditions with high diagnosed prevalence (cardiovascular, diabetes, oncology, respiratory) and conditions requiring ongoing pharmaceutical management. Rare diseases are identifiable but require larger databases or pooled multi-country data to achieve sufficient sample sizes for meaningful analysis.

Q: What’s the difference between diagnosed prevalence and true prevalence in claims data?

Claims data captures diagnosed prevalence—patients with medical encounters generating diagnosis codes. This systematically underestimates true prevalence for conditions with low diagnosis rates or asymptomatic phases. For conditions like hypertension or diabetes where diagnosis and monitoring are routine, diagnosed prevalence closely approximates true prevalence. For underdiagnosed or stigmatized conditions, expect meaningful underestimation—and plan your analyses accordingly.

Q: How do we validate data quality before committing to large projects?

Request sample data for your therapeutic area. Check age/sex distributions against published epidemiological literature, coding quality and completeness, longitudinal tracking capabilities, and comparability to benchmark sources like Eurostat, ECDC, or national statistics bureau publications. Review documentation quality: data dictionaries, schema descriptions, validation reports. Reputable providers can demonstrate their validation methodology transparently—if they can’t, that’s a signal worth taking seriously.

Q: Can we combine Pan-European claims data with our clinical trial data?

Not at individual patient level without explicit consent obtained at enrollment. But you can absolutely use Pan-European claims data to create matched external control cohorts, benchmark trial outcomes against real-world performance, contextualize trial populations within the broader patient landscape, and design enrichment strategies for future trials. These applications are becoming standard practice in rare diseases and oncology particularly.

Making Pan-European Epidemiology Data Work for Your Organization

Here’s what most companies get wrong: they treat epidemiology data as a one-time purchase rather than a strategic capability.

The pharma and MedTech organizations seeing the highest ROI from Pan-European data share specific practices:

Build internal expertise at the intersection of clinical and analytical

You need people who understand both therapeutic context and the technical realities of claims data across different healthcare systems. That intersection—clinicians who understand data, data scientists who understand disease pathways—is where genuine insight emerges. Investing in this capability internally makes every external data investment more productive.

Establish long-term data strategy, not project-by-project procurement

Working with consistent data sources and analytical frameworks across multiple projects means faster turnaround, better comparability across analyses, and cumulative institutional knowledge about your therapeutic areas. One-off data purchases rarely build the kind of evidence base that impresses HTA reviewers or shapes long-term market access strategy.

Integrate data into strategic decision workflows

Don’t let data sit in presentation decks. Embed Pan-European RWE into brand planning, launch strategy, medical affairs activities, regulatory submissions, and commercial forecasting. When market access teams automatically ask “What does the claims data show?” before every major decision—that’s operational maturity.

Think longitudinally, not cross-sectionally

The real power of Pan-European claims data is temporal: treatment sequences, switching patterns, outcomes trajectories, healthcare utilization over time. Design analyses to leverage this longitudinal depth rather than extracting simple point-in-time snapshots.

Leverage expert guidance for source selection

The gap between understanding what epidemiology data can do and identifying which specific source matches your needs is substantial. The data landscape includes dozens of providers with overlapping but distinct capabilities across country coverage, recency, analytical tools, GDPR compliance infrastructure, and therapeutic depth. Expert advisors who understand both your business objectives and the vendor landscape can accelerate your path to value while preventing costly mismatches—and this guidance pays for itself many times over in avoided wrong turns.

Plan evidence generation before launch, not after

Phase II is when sophisticated teams start mapping Pan-European RWE strategy: What epidemiological evidence will we need? What claims analyses support our value story? How do we position against existing treatments in real-world data? Companies that wait until post-approval to think about Continental European RWE are already behind—and will feel that gap acutely during reimbursement negotiations.

The Bottom Line: Why This Matters Now

Continental Europe’s healthcare landscape is at an inflection point. Digitalization, expanding RWE requirements from HTA bodies and regulators, EHDS implementation, and maturing AI/ML capabilities are converging to make epidemiology data more valuable—and more essential—than ever before.

Making strategic decisions about Continental European markets without comprehensive, validated, population-representative data means operating on assumption rather than evidence. In markets this sophisticated, with regulatory requirements this stringent, that’s an increasingly untenable position.

The infrastructure exists. The methodological frameworks are established. The regulatory pathways are increasingly clear. What distinguishes leaders from followers now is execution: identifying the right data sources, building internal analytical capabilities, and embedding Pan-European RWE into strategic planning from the earliest stages of product development.

Whether you’re sizing a major market opportunity or preparing your first HTA dossier, Pan-European epidemiology datasets provide the foundation. The question isn’t whether this data matters—it’s whether you’re positioned to leverage it effectively, and whether you have the right guidance to navigate the landscape before your competitors do.

Your Next Steps

If you’re evaluating Pan-European epidemiology datasets for your organization, the most valuable first step is clarity on requirements—not vendor selection.

Define your use case precisely: market sizing, HEOR, patient journey analysis, pharmacovigilance, trial feasibility. Identify the granularity you actually need. Understand your GDPR compliance constraints, any country-specific data protection requirements, and your timeline. Only then does evaluating data sources become productive—because you’re comparing options on dimensions that genuinely matter for your situation.

The claims data landscape is complex, with significant variation across providers in country coverage, analytical capabilities, compliance infrastructure, and cost models. Expert guidance at the selection and scoping stage consistently shortens timelines, reduces risk, and improves analytical outcomes for teams entering this space or expanding their Pan-European RWE capabilities.

Ready to explore how Pan-European epidemiology data can support your specific strategic objectives? Contact us to discuss your requirements and explore the right approach for your situation →

Sources & References

European Medicines Agency. (2023). Real-world evidence framework to support EU regulatory decision-making: Report on experience gained with regulator-led studies (September 2021–February 2023). https://www.ema.europa.eu/…
Walker, J., Knaack, M., & Volkmer, S. (2022). Sampling strategy, characteristics and representativeness of the InGef research database. Pharmacoepidemiology and Drug Safety, 31(7), 793–804. https://pubmed.ncbi.nlm.nih.gov/35378455/
Haug, U., & Schink, T. (2021). German Pharmacoepidemiological Research Database (GePaRD). In: Databases for Pharmacoepidemiological Research. Springer, Cham. https://link.springer.com/…
Ohlmeier, C., et al. (2019). Epidemiology and health care utilization of patients suffering from Huntington’s disease in Germany. BMC Neurology, 19(1), 318. https://pubmed.ncbi.nlm.nih.gov/31823737/
Weißbrich, C., et al. (2025). Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data. Annals of Hematology. https://link.springer.com/…
Berber, A., et al. (2024). Estimating excess mortality and economic burden of Clostridioides difficile infections in Germany (RECUR Germany). BMC Infectious Diseases, 24(1), 585. https://link.springer.com/…
Helfer, S., et al. (2021). Generating Enriched Synthetic Hospital Claims Data—A Use Case Driven Approach. Studies in Health Technology and Informatics, 281, 669–673. https://pubmed.ncbi.nlm.nih.gov/34042876/
Swart, E., et al. (2016). Status and perspectives of claims data analyses in Germany—A systematic review. Health Policy, 120(2), 213–226. https://www.sciencedirect.com/…
Di Stasio, M., et al. (2023). Real-world evidence: methodological issues and opportunities from the European Health Data Space. BMC Medical Research Methodology, 23(1), 178. https://bmcmedresmethodol.biomedcentral.com/…

Related Resources

Explore More:

MEDDDICAL is an expert advisory and strategic consultancy helping pharma, biotech, and MedTech companies navigate the complex Pan-European real-world evidence data landscape—from requirements definition through source selection, compliance structuring, and evidence strategy implementation.